1. Home
  2. PONO vs PYXS Comparison

PONO vs PYXS Comparison

Compare PONO & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PONO

Pono Capital Four Inc. Class A Ordinary Shares

N/A

Current Price

$10.07

Market Cap

174.2M

Sector

Finance

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

N/A

Current Price

$1.69

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PONO
PYXS
Founded
2026
2018
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.2M
141.3M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
PONO
PYXS
Price
$10.07
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $8.22
AVG Volume (30 Days)
12.8K
★ 718.0K
Earning Date
11-19-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.03
EPS
★ N/A
N/A
Revenue
N/A
★ $13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.95
$1.03
52 Week High
$10.09
$5.55

Technical Indicators

Market Signals
Indicator
PONO
PYXS
Relative Strength Index (RSI) 71.53 40.32
Support Level $10.02 $1.29
Resistance Level $10.09 $1.77
Average True Range (ATR) 0.01 0.15
MACD 0.00 0.02
Stochastic Oscillator 100.00 43.50

Price Performance

Historical Comparison
PONO
PYXS

About PONO Pono Capital Four Inc. Class A Ordinary Shares

Pono Capital Four Inc is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: